OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated ...

IMUNON (IMNN) announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of ...

Ardena Acquired Catalent’s Somerset, NJ, oral solids development and small-scale drug product manufacturing facility for an undisclosed price, in a deal completed in February. In Somerset, expanded ...

In this GEN webinar, our expert speakers will present a case study demonstrating the exceptional properties and high-fidelity performance of ENFINIA Linear DNA.

The case raised concerns about whether Chinese nationals were part of a campaign to terrorize the U.S. agricultural industry ...

University of Iowa researchers developed a gene therapy that could prevent craniosynostosis, a condition where babies’ skull ...

The Global DNA Manufacturing Market is estimated to be valued at USD 6.44 Bn in 2025 and is expected to reach USD 19.56 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.2% from 2025 ...

ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced the appointment of Larry Lockwood, Ph.D., as Chief Commercial Officer. Dr.

Quotient Sciences has entered a partnership with the UK's CPI to expedite the creation of RNA-based treatments ...

The webcast will be available for 90 days at the link above or under the News & Investors tab of the Imunon website at IMUNON is a clinical-stage biotechnology company focused on advancing a ...

The authors argue that male-biased expression of Cyp17a2 is implicated in mediating infection levels through STING and USP8 activity regulation. Thus, this study highlights an unexpected factor ...

Quotient Sciences and CPI to Accelerate RNA Drug Development with Joint Venture  Nottingham, UK, September 2, 2025 – Quotient Sciences, a leading global drug development and manufacturing accelerator, ...